CYTLIMIC

cytlimic-logo

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.

#People #Financial #Website #More

CYTLIMIC

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2016-12-16

Address:
Higashi-shinagawa, Tokyo, Japan

Country:
Japan

Website Url:
http://www.cytlimic.com

Total Employee:
1+

Status:
Active

Total Funding:
20.85 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx



Current Advisors List

not_available_image

Fujikawa Osamu Executive Officer @ Cytlimic
Board_member

not_available_image

Toi Shun Chairman @ Cytlimic
Board_member

not_available_image

Hiromichi Kimura Directors @ Cytlimic
Board_member

not_available_image

Ken Nakamura Director @ Cytlimic
Board_member

not_available_image

Koichi Niide Auditor @ Cytlimic
Board_member

Current Employees Featured

not_available_image

Minori Saito
Minori Saito Chief Executive Officer, President & Board Member @ Cytlimic
Chief Executive Officer, President & Board Member

not_available_image

Yoshihide segawa
Yoshihide segawa Chief Operating Officer @ Cytlimic
Chief Operating Officer
2017-04-01

Founder


shun-doi_image

Shun Doi

Investors List

smbc-venture-capital_image

SMBC Venture Capital

SMBC Venture Capital investment in Series B - Cytlimic

fast-track-initiative_image

Fast Track Initiative, Inc.

Fast Track Initiative, Inc. investment in Series B - Cytlimic

nec-capital-solution_image

NEC Capital Solutions

NEC Capital Solutions investment in Series B - Cytlimic

fast-track-initiative_image

Fast Track Initiative, Inc.

Fast Track Initiative, Inc. investment in Seed Round - Cytlimic

fast-track-initiative_image

Fast Track Initiative, Inc.

Fast Track Initiative, Inc. investment in Series A - Cytlimic

nec-capital-solution_image

NEC Capital Solutions

NEC Capital Solutions investment in Series A - Cytlimic

smbc-venture-capital_image

SMBC Venture Capital

SMBC Venture Capital investment in Series A - Cytlimic

Official Site Inspections

http://www.cytlimic.com

  • Host name: server-3-167-99-116.iad55.r.cloudfront.net
  • IP address: 3.167.99.116
  • Location: Seattle United States
  • Latitude: 47.6348
  • Longitude: -122.3451
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98109

Loading ...

More informations about "Cytlimic"

Cytlimic - Crunchbase Company Profile & Funding

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune …See details»

CYTLIMIC Company Profile - Office Locations, Competitors ... - Craft

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer. It specializes in clinical trials and nonclinical testing of cancer peptide vaccines as well …See details»

Cytlimic Company Profile 2024: Valuation, Funding & Investors

Cytlimic is headquartered in Tokyo, Japan. What industry is Cytlimic in? Cytlimic’s primary industry is Drug Discovery. Is Cytlimic a private or public company? Cytlimic is a Private …See details»

CYTLIMIC, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Nov 1, 2024 Explore CYTLIMIC, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news, and 5 literature, Disease Domain:Neoplasms, Technology …See details»

Cytlimic - Contacts, Employees, Board Members, Advisors & Alumni

Organization. Cytlimic . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Employee Profiles 2. Number of Board Member and Advisor Profiles 5. …See details»

CYTLIMIC Inc - Company Profile and News - Bloomberg Markets

Company profile page for CYTLIMIC Inc including stock price, company news, executives, board members, and contact informationSee details»

Cytlimic - Crunchbase

CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. Search Crunchbase Start Free TrialSee details»

NEC ventures into the drug discovery business: pursuing the …

On December 19, 2016, as part of efforts to strengthen its healthcare business, NEC announced the establishment of CYTLIMIC Inc., a new company that promotes the development and …See details»

CYTLIMIC - Products, Competitors, Financials, Employees, …

About CYTLIMIC. CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC's products aim to …See details»

NEC drug development investment, CYTLIMIC, secures 1.3 billion …

Aug 9, 2019 NEC Corporation (NEC; TSE: 6701) and CYTLIMIC Inc. today announced that financing of 1.3 billion yen (around US$ 12 million at current rate) was completed through the …See details»

NEC aims to discover new drugs harnessing advanced AI technology

Tokyo, December 19, 2016 - NEC Corporation (NEC; TSE: 6701) today announced the establishment of "CYTLIMIC Inc." (CYTLIMIC), a new company that promotes the …See details»

Cytlimic - Funding, Financials, Valuation & Investors - Crunchbase

How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Aug 9, 2019: Series B - …See details»

CYTLIMIC For personal use only - Australian Securities Exchange

Jan 7, 2019 CYTLIMIC’s current lead product candidate CYT001 is a combination of two multiple-HLA peptides for HSP70 and GPC3 antigens, and LAG-3Ig (Eftilagimod Alpha) and …See details»

PRIMA BIOMED ENTERS NEW MATERIAL TRANSFER AGREEMENT …

CYTLIMIC, a recent spin off from NEC Corporation (NEC), is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide …See details»

Phase I study of a new concept cancer vaccine composed artificial ...

Background: CYT001 (CYTLIMIC Inc.) is a novel cancer vaccine involving artificial intelligence (AI)-designed shared-antigen peptides and optimal combined adjuvants that boost the cancer …See details»

Cytlimic - Updates, News, Events, Signals & Triggers - Crunchbase

CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine.See details»

CYTLIMIC, Inc.: Drug pipelines, Patents, Clinical trials - Synapse

May 30, 2023 Explore CYTLIMIC, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news.See details»

Immutep Enters into Clinical Trial Collaboration, Service and …

Jan 7, 2019 CYTLIMIC also has unique intellectual properties of a combination of LAG-3 IgG fusion protein and Poly IC to synergistically boost the effect of peptide vaccine antigens. …See details»

Cytlimic - Tech Stack, Apps, Patents & Trademarks - Crunchbase

The intellectual property of Cytlimic includes 5 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Cytlimic has …See details»

Immutep Enters Into Clinical Trial Collaboration, Service

Jan 7, 2019 CYTLIMIC’s current lead product candidate CYT001 is a combination of two multiple-HLA peptides for HSP70 and GPC3 antigens, and LAG-3Ig (Eftilagimod Alpha) and …See details»

linkstock.net © 2022. All rights reserved